Jeff Eiseman
Long only, deep value, special situations

How An Improved Damages Award Against SIGA Would Affect PharmAthene's Valuation

This article is about a legal dispute between PharmAthene (NYSEMKT:PIP) and SIGA (NASDAQ:SIGA) that I discussed in a previous article, and in its predecessor, both of which relate to a 2011 ruling by Vice Chancellor Parsons, and the Delaware Supreme Court's May 24, 2013 response, which remanded damages-related issues to the Vice Chancellor. On June 26, the Vice Chancellor held a status conference to discuss how to proceed. Below I describe what happened during the meeting that is relevant to valuing PharmAthene, discuss a new legal issue introduced and describe a damages remedy that, I argue, would be more equitable, less likely to be subject to manipulation by SIGA, and less susceptible to be...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details